Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FDA018-ADC in taxane-resistant triple-negative breast cancer
NCT06519370Phase 3Active, not recruiting
- Sponsor
- Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.
- Start
- Aug 2024
- Primary completion
- Aug 2026
- Modality
- Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
A Phase 3 trial of FDA018-ADC in triple-negative breast cancer (TNBC), sponsored by Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.. Started Aug 2024; status: active, not recruiting.
02
Drugs
FDA018-ADC
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT06519370.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06519370.